Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
melanoma (56) 56
humans (55) 55
index medicus (48) 48
oncology (42) 42
male (35) 35
female (34) 34
middle aged (30) 30
immunotherapy (26) 26
aged (25) 25
cancer (25) 25
ipilimumab (24) 24
adult (23) 23
dermatology (23) 23
metastatic melanoma (22) 22
melanoma - drug therapy (20) 20
human necessities (19) 19
hygiene (19) 19
medical or veterinary science (19) 19
preparations for medical, dental, or toilet purposes (19) 19
pembrolizumab (18) 18
skin (18) 18
therapy (17) 17
metastasis (16) 16
nivolumab (16) 16
skin cancer (15) 15
aged, 80 and over (14) 14
animals (14) 14
care and treatment (14) 14
immunology (14) 14
skin neoplasms - drug therapy (14) 14
antibodies, monoclonal - therapeutic use (13) 13
biochemistry (13) 13
melanoma - pathology (13) 13
microbiology (13) 13
patients (13) 13
survival (13) 13
chemistry (12) 12
medicine, research & experimental (12) 12
analysis (11) 11
antibodies, monoclonal - adverse effects (11) 11
beer (11) 11
compositions thereof (11) 11
culture media (11) 11
enzymology (11) 11
metallurgy (11) 11
microorganisms or enzymes (11) 11
mutation or genetic engineering (11) 11
propagating, preserving or maintaining microorganisms (11) 11
retrospective studies (11) 11
specific therapeutic activity of chemical compounds ormedicinal preparations (11) 11
spirits (11) 11
vinegar (11) 11
wine (11) 11
antineoplastic agents - adverse effects (10) 10
antineoplastic agents - therapeutic use (10) 10
complications and side effects (10) 10
melanoma - therapy (10) 10
cell death (9) 9
immune checkpoint (9) 9
metastases (9) 9
mice (9) 9
treatment outcome (9) 9
immunotherapy - methods (8) 8
interleukin-12 - genetics (8) 8
malignant-melanoma (8) 8
melanoma - secondary (8) 8
programmed cell death 1 receptor - antagonists & inhibitors (8) 8
risk factors (8) 8
safety (8) 8
skin neoplasms - pathology (8) 8
advanced melanoma (7) 7
antibodies (7) 7
apoptosis (7) 7
biomarker (7) 7
braf (7) 7
cell lung-cancer (7) 7
cutaneous melanoma (7) 7
diagnosis (7) 7
hematology, oncology and palliative medicine (7) 7
inhibitors (7) 7
medical prognosis (7) 7
medicine (7) 7
medizinische fakultät (7) 7
melanoma - genetics (7) 7
myocarditis (7) 7
neoplasm metastasis (7) 7
regression analysis (7) 7
research (7) 7
research article (7) 7
survival analysis (7) 7
tumors (7) 7
young adult (7) 7
internal medicine (6) 6
lymphocytes (6) 6
melanoma - mortality (6) 6
prognosis (6) 6
radiation (6) 6
usage (6) 6
vemurafenib (6) 6
adverse events (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Correspondence
by Heinzerling, Lucie
Deutsches Aerzteblatt Online, ISSN 1866-0452, 05/2019
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
by Voskens, Caroline J and Goldinger, Simone M and Loquai, Carmen and Robert, Caroline and Kaehler, Katharina C and Berking, Carola and Bergmann, Tanja and Bockmeyer, Clemens L and Eigentler, Thomas and Fluck, Michael and Garbe, Claus and Gutzmer, Ralf and Grabbe, Stephan and Hauschild, Axel and Hein, Rüdiger and Hundorfean, Gheorghe and Justich, Armin and Keller, Ullrich and Klein, Christina and Mateus, Christine and Mohr, Peter and Paetzold, Sylvie and Satzger, Imke and Schadendorf, Dirk and Schlaeppi, Marc and Schuler, Gerold and Schuler-Thurner, Beatrice and Trefzer, Uwe and Ulrich, Jens and Vaubel, Julia and von Moos, Roger and Weder, Patrik and Wilhelm, Tabea and Göppner, Daniela and Dummer, Reinhard and Heinzerling, Lucie M
PLoS ONE, ISSN 1932-6203, 01/2013, Volume 8, Issue 1, p. e53745
Background: Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces... 
REGRESSION | TRIAL | INDUCED SARCOIDOSIS | CTLA-4 BLOCKADE | AUTOIMMUNITY | SAFETY | MULTIDISCIPLINARY SCIENCES | MONOCLONAL-ANTIBODY | PATIENT | HYPOPHYSITIS | CANCER | Antimitotic agents | Antigens | Care and treatment | Algorithms | Lymphocytes | Melanoma | Skin | Metastasis | Antineoplastic agents | Skin cancer | Cancer | Aseptic meningitis | Guillain-Barre syndrome | Exanthema | Central nervous system | Blocking antibodies | Cytotoxicity | Oncology | Lymphocytes T | Metastases | CTLA-4 protein | Intestine | Gastroenterology | Meningitis | Internal medicine | Hematology | Sarcoidosis | Dermatology | Management | Regression analysis | Patients | Eosinophilia | Morbidity | Inflammatory bowel disease | Pathology | Side effects | Hospitals | Perforations | Medical prognosis | Antitumor activity | Autoimmune diseases | Endocrinology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text In Reply
by Heinzerling, Lucie
Deutsches Arzteblatt international, 05/2019, Volume 116, Issue 20, p. 363
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Correspondence (reply): In Reply
by Heinzerling, Lucie
Deutsches Ärzteblatt International, 5/2019, Volume 116, Issue 20, pp. 363 - 363
Correspondence
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma
by Lisa Walter and Lucie Heinzerling
Anticancer Research, ISSN 0250-7005, 03/2018, Volume 38, Issue 3, p. 1335
Background/Aim: Recent evidence suggests that melanoma patients treated with BRAF inhibitors experience radiosensitization with an increased frequency of... 
Biotechnology | Ionizing radiation | Inhibitors | Radiosensitization | Cell survival | Cell death | Test procedures | Melanoma | Tumor cell lines | Survival | Necrosis
Journal Article
Details down arrow
6. Full Text Therapy preferences in melanoma treatment - willingness to pay and preference of quality versus length of life of patients, physicians and healthy controls
by Krammer, Ramona and Krammer, Ramona and Heinzerling, Lucie and Heinzerling, Lucie
PloS one, ISSN 1932-6203, 2014, Volume 9, Issue 11, p. e111237
Background: New melanoma therapies, like e. g. ipilimumab, improve survival. However, only a small subset of patients benefits while 60% encounter side... 
CELL LUNG-CANCER | BREAST-CANCER | METASTATIC MELANOMA | COST | MULTIDISCIPLINARY SCIENCES | MELANOGENESIS | OVARIAN-CANCER | CARE NEAR-DEATH | IPILIMUMAB | CHEMOTHERAPY | PROGRESSION | Skin Neoplasms - drug therapy | Age Factors | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Palliative Care | Antineoplastic Agents - therapeutic use | Young Adult | Skin Neoplasms - economics | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Surveys and Questionnaires | Quality-Adjusted Life Years | Attitude to Health | Longevity | Cost-Benefit Analysis | Melanoma - drug therapy | Melanoma - economics | Quality of Life | Vomiting - etiology | Patients - psychology | Aged | Physicians - psychology | Surveys | Antimitotic agents | Medical care | Antineoplastic agents | Melanoma | Quality management | Drugs | Medical personnel | Therapy | Statistical analysis | Dermatology | Physicians | Elasticity | Metastasis | Cancer therapies | Survival | Patients | Quality of life | Ethics | Side effects | Chemotherapy | Hospitals | Health care expenditures | Response rates | Palliative care | Informed consent
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
by Mahmood, Syed S and Fradley, Michael G and Cohen, Justine V and Nohria, Anju and Reynolds, Kerry L and Heinzerling, Lucie M and Sullivan, Ryan J and Damrongwatanasuk, Rongras and Chen, Carol L and Gupta, Dipti and Kirchberger, Michael C and Awadalla, Magid and Hassan, Malek Z.O and Moslehi, Javid J and Shah, Sachin P and Ganatra, Sarju and Thavendiranathan, Paaladinesh and Lawrence, Donald P and Groarke, John D and Neilan, Tomas G
Journal of the American College of Cardiology, ISSN 0735-1097, 04/2018, Volume 71, Issue 16, pp. 1755 - 1764
Myocarditis is an uncommon, but potentially fatal, toxicity of immune checkpoint inhibitors (ICI). Myocarditis after ICI has not been well characterized. The... 
pembrolizumab | cardio-oncology | nivolumab | myocarditis | ipilimumab | checkpoint inhibitor | SURVIVAL | CARDIAC & CARDIOVASCULAR SYSTEMS | PROGNOSTIC VALUE | LATE GADOLINIUM ENHANCEMENT | FULMINANT | METASTATIC MELANOMA | ANTI-PD-1 THERAPY | SUSPECTED MYOCARDITIS | MAGNETIC-RESONANCE | BLOCKADE | Myocarditis | Care and treatment | Heart | Statistical analysis | Toxicity | Diabetes mellitus | Melanoma | Medical records | Cancer therapies | Patients | Regulatory approval | Troponin T | Confidence intervals | Side effects | Troponin | Inhibitors | Immune checkpoint | Calcium-binding protein | Blood pressure | Heart diseases | Steroid hormones | Ejection | Steroids
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Senescence markers: Predictive for response to checkpoint inhibitors
by Moreira, Alvaro and Gross, Stefanie and Kirchberger, Michael Constantin and Erdmann, Michael and Schuler, Gerold and Heinzerling, Lucie
International Journal of Cancer, ISSN 0020-7136, 03/2019, Volume 144, Issue 5, pp. 1147 - 1150
Recent studies suggest that the age‐related remodeling of the immune system, known as immunosenescence, could impact the efficacy of immune checkpoint... 
melanoma | immunosenescence | immune checkpoint inhibitors | biomarker | BIOMARKERS | CELLS | ONCOLOGY | CD57 antigen | CD27 antigen | Flow cytometry | Therapy | Phenotypes | Senescence | Leukemia | Lung cancer | Melanoma | Lymphocytes T | CD28 antigen | Patients | Metastases | Inhibitors | Immune checkpoint | Lymphocytes | Correlation analysis | Phenotyping | Peripheral blood | Biomarkers | Immunosenescence | Surface markers | Immune system
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text MYOCARDITIS IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS
by Mahmood, Syed and Fradley, Michael G and Cohen, Justine V and Nohria, Anju and Reynolds, Kerry L and Heinzerling, Lucie M and Sullivan, Ryan J and Damrongwatanasuk, Rongras and Chen, Carol and Gupta, Dipti and Kirchberger, Michael C and Moslehi, Javid and Shah, Sachin and Ganatra, Sarju and Thavendiranathan, Paaladinesh and Lawrence, Donald P and Groarke, John D and Neilan, Tomas G
Journal of the American College of Cardiology, ISSN 0735-1097, 03/2018, Volume 71, Issue 11, pp. A699 - A699
Major adverse cardiac events (MACE) were defined as a composite of cardiovascular death, cardiogenic shock, cardiac arrest and complete heart block. Conclusion... 
Myocarditis | Heart diseases | Immune checkpoint
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text The skin prick test - European standards
by Heinzerling, Lucie and Mari, Aiano and Bergmann, Karl-Christian and Bresciani, Megon and Burbach, Guido and Darsow, Ulf and Durham, Stephen and Fokkens, Wytske and Gjomarkaj, Mark and Haahtela, Tari and Bom, Ana Todo and Wöhrl, Stefan and Maibach, Howard and Lockey, Richard
Clinical and translational allergy, ISSN 2045-7022, 2013, Volume 3, Issue 1, pp. 1 - 10
Skin prick testing is an essential test procedure to confirm sensitization in IgE-mediated allergic disease in subjects with rhinoconjunctivitis, asthma,... 
Diagnostic test | Type I allergy | Skin prick test panel | Aallergies | Sensitization | Asthma | Inhalant allergens | Allergy | Allergens | Meetings | Analysis | Immunoglobulin E | Skin | Allergic reaction
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Eosinophil-cationic protein: A novel liquid prognostic biomarker in melanoma
by Moreira, Alvaro and Krueckel, Annika and Schuler, Gerold and Heinzerling, Lucie
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. e21573 - e21573
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Braf inhibitors and radiation do not act synergistically to inhibit WT and V600E BRAF human melanoma
by Walter, Lisa and Heinzerling, Lucie
Anticancer Research, ISSN 0250-7005, 03/2018, Volume 38, Issue 3, pp. 1335 - 1341
Background/Aim: Recent evidence suggests that melanoma patients treated with BRAF inhibitors experience radiosensitization with an increased frequency of... 
Vemurafenib | V600E mutant BRAF | Melanoma | Dabrafenib | BRAF inhibitor | BRAF | Radiotherapy | SURVIVAL | ONCOLOGY | radiotherapy | vemurafenib | MUTATIONS | dabrafenib | STRATEGIES
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Eosinophil-cationic protein - a novel liquid prognostic biomarker in melanoma
by Kruckel, A and Moreira, A and Frohlich, W and Schuler, G and Heinzerling, L
BMC CANCER, ISSN 1471-2407, 03/2019, Volume 19, Issue 1, pp. 207 - 7
BackgroundThe role of eosinophils in cancer is not yet completely understood, but patients with eosinophilia show a trend towards longer survival in several... 
CELLS | Biomarker | Prognosis | MIA | Melanoma | Eosinophil cationic protein (ECP) | SERUM | CANCER | INFILTRATION | METASTATIC MELANOMA | LDH | ECP | ONCOLOGY | CARCINOMA | Eosinophils
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Management of side effects of immune checkpoint blockade by anti‐CTLA‐4 and anti‐PD‐1 antibodies in metastatic melanoma
by Kähler, Katharina C and Hassel, Jessica C and Heinzerling, Lucie and Loquai, Carmen and Mössner, Rotraut and Ugurel, Selma and Zimmer, Lisa and Gutzmer, Ralf and Cutaneous Side Effects and “Cutaneous Side Effects” Committee of the Work Group Dermatological Oncology (ADO)
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 07/2016, Volume 14, Issue 7, pp. 662 - 681
Summary CTLA‐4 and PD‐1 are potential targets for tumor‐induced downregulation of lymphocytic immune responses. Immune checkpoint‐modifying monoclonal... 
melanoma | side effect management | autoimmune side effects | CTLA‐4 antibody | PD‐1 antibody | immune checkpoint blockade | CTLA-4 antibody | PD-1 antibody | CELL LUNG-CANCER | UNTREATED MELANOMA | THERAPY | PEMBROLIZUMAB | LONG-TERM SAFETY | PHASE-3 TRIAL | HYPOPHYSITIS | NIVOLUMAB | ADVERSE EVENTS | IPILIMUMAB | DERMATOLOGY | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Melanoma - drug therapy | Antibodies, Monoclonal - adverse effects | Antineoplastic Agents | CTLA-4 Antigen - antagonists & inhibitors | Drug-Related Side Effects and Adverse Reactions - therapy | Monoclonal antibodies | Complications and side effects | Metastasis | T cells | Analysis | Melanoma | Immunoglobulins | T cell receptors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text A review of serious adverse effects under treatment with checkpoint inhibitors
by Heinzerling, Lucie and Goldinger, Simone M
Current Opinion in Oncology, ISSN 1040-8746, 03/2017, Volume 29, Issue 2, pp. 136 - 144
PURPOSE OF REVIEWThe aim of this article is to raise awareness of physicians for the serious side-effects of immune-checkpoint blocking antibodies. As... 
cardiotoxicity | autoimmunity | hepatitis | endocrinopathies | pneumonitis | MONOCLONAL-ANTIBODY | CELL LUNG-CANCER | RENAL-ALLOGRAFT REJECTION | METASTATIC MELANOMA | NIVOLUMAB TREATMENT | ANTI-PD-1 THERAPY | ONCOLOGY | TRANSPLANT RECIPIENT | ORGANIZING PNEUMONIA | PANCREATITIS SECONDARY | IPILIMUMAB TREATMENT | Antibodies, Monoclonal - therapeutic use | Neoplasms - immunology | Humans | Antibodies, Monoclonal - adverse effects | Neoplasms - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text C-reactive protein as an early marker of immune-related adverse events
by Abolhassani, Amir-Reza and Schuler, Gerold and Kirchberger, Michael Constantin and Heinzerling, Lucie
Journal of Cancer Research and Clinical Oncology, ISSN 0171-5216, 10/2019, Volume 145, Issue 10, pp. 2625 - 2631
Immune checkpoint inhibitors (ICIs) are effective against a wide variety of cancers. However, they also induce a plethora of unique immune-related adverse... 
C-reactive protein | Medicine & Public Health | Hematology | Adverse events | Melanoma | Oncology | Cancer Research | Internal Medicine | Immune checkpoint inhibitors | SURVIVAL | SAFETY | ANTIBODY | TOXICITY | PEMBROLIZUMAB | ONCOLOGY | BLOCKADE | IPILIMUMAB | BLOOD | Proteins | Complications and side effects | Medical research | Analysis | Communicable diseases | Medicine, Experimental | Development and progression
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Nebenwirkungsmanagement bei Immun‐Checkpoint‐Blockade durch CTLA‐4‐ und PD1‐Antikörper beim metastasierten Melanom
by Kähler, Katharina C and Hassel, Jessica C and Heinzerling, Lucie and Loquai, Carmen and Mössner, Rotraut and Ugurel, Selma and Zimmer, Lisa and Gutzmer, Ralf and für das Komitee „Kutane Nebenwirkungen“ der Arbeitsgemeinschaft Dermatologische Onkologie (ADO)
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 07/2016, Volume 14, Issue 7, pp. 662 - 683
Zusammenfassung CTLA‐4 und PD‐1 sind mögliche Angriffspunkte für eine Tumor‐bedingte Herunterregulation lymphozytärer Immunantworten.... 
Antigens | Hepatitis | Cell death
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors
by Moreira, Alvaro and Loquai, Carmen and Pföhler, Claudia and Kähler, Katharina C and Knauss, Samuel and Heppt, Markus V and Gutzmer, Ralf and Dimitriou, Florentia and Meier, Friedegund and Mitzel-Rink, Heidrun and Schuler, Gerold and Terheyden, Patrick and Thoms, Kai-Martin and Türk, Matthias and Dummer, Reinhard and Zimmer, Lisa and Schröder, Rolf and Heinzerling, Lucie
European Journal of Cancer, ISSN 0959-8049, 01/2019, Volume 106, pp. 12 - 23
To characterise clinical presentation, laboratory and histopathologic characteristics and assess the treatment and outcome of neuromuscular side-effects of... 
Neuromuscular side effects | Myositis | Immune checkpoint inhibitors | Tocilizumab | DERMATOMYOSITIS | SAFETY | OPEN-LABEL | CELL LUNG-CANCER | IPILIMUMAB THERAPY | ADVERSE EVENT | PEMBROLIZUMAB | ONCOLOGY | ADVANCED MELANOMA | PATIENT | NIVOLUMAB | Complications and side effects | Creatine | Skin cancer | Therapy | PD-1 protein | Creatine kinase | Clinical trials | Antibodies | Metastases | Proteins | Pembrolizumab | Myasthenia gravis | Immunotherapy | Heart diseases | Movement disorders | Neuromuscular diseases | Complications | Patients | Myocarditis | Side effects | Inhibitors | Immune checkpoint | Cell death | Polymyalgia rheumatica | Neuromuscular junctions | Muscle function | Skin | Myasthenia | Steroid hormones | Steroids | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights